{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-017040","form_type":"8-K","ticker":"GOVX","cik":"0000832489","company_name":"GeoVax Labs, Inc.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.104662+00:00","generated_at":"2026-06-01T23:55:10.340945+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"GeoVax Q1 net loss widens to $5.6M; cash drops to $0.8M, raising going-concern risk","bullets":["Net loss of $5.6M ($2.47 per share) vs $4.0M ($2.30 per share) in Q1 2023.","Cash balance fell to $768,859 from $6.45M at Dec 31, 2023, a decline of ~$5.7M.","R&D expenses rose to $4.43M from $2.82M, driven by manufacturing costs for clinical trials.","Phase 2 GEO-CM04S1 COVID vaccine booster trial showed statistically significant neutralizing antibody increases against multiple variants.","Gedeptin Phase 1/2 for head and neck cancer completed enrollment; expected to complete Q3 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-017040","json":"https://secwatch.observer/filing/0001437749-24-017040.json","markdown":"https://secwatch.observer/filing/0001437749-24-017040.md","text":"https://secwatch.observer/filing/0001437749-24-017040.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/832489/000143774924017040/0001437749-24-017040-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/832489/000143774924017040/govx20240514_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T23:55:10.340945+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bfcacf5593956e9cd54bee33fdb61b9da0bbe678","claim":"GeoVax Labs, Inc. reported financial results for first quarter ended March 31, 2024.","evidence_excerpt":"On May 14, 2024, GeoVax Labs, Inc. (the “Company”) issued a press release reporting its results of operations for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/832489/000143774924017040/0001437749-24-017040-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}